- Home
- MRNA vs QGEN Comparison
MRNA vs QGEN Comparison
Compare MRNA & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | QGEN |
|---|---|---|
| Founded | 2010 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.2B |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MRNA | QGEN |
|---|---|---|
| Price | $32.80 | $45.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $33.25 | ★ $50.07 |
| AVG Volume (30 Days) | ★ 10.6M | 1.2M |
| Earning Date | 02-13-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 3.31% |
| EPS Growth | N/A | ★ 331.20 |
| EPS | N/A | ★ 1.84 |
| Revenue | ★ $2,232,000,000.00 | $2,070,781,000.00 |
| Revenue This Year | N/A | $7.12 |
| Revenue Next Year | $0.77 | $6.13 |
| P/E Ratio | ★ N/A | $24.80 |
| Revenue Growth | N/A | ★ 5.32 |
| 52 Week Low | $22.28 | $37.63 |
| 52 Week High | $48.92 | $51.88 |
Technical Indicators
Market Signals| Indicator | MRNA | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 66.19 | 46.57 |
| Support Level | $32.14 | $44.51 |
| Resistance Level | $35.90 | $46.17 |
| Average True Range (ATR) | 1.65 | 0.68 |
| MACD | 0.49 | -0.03 |
| Stochastic Oscillator | 70.53 | 32.66 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).